| Name | Title | Contact Details |
|---|
At orthobrain®, we have reinvented the delivery of orthodontics, providing access to more people and providing dentists the opportunity to offer excellent orthodontic care to their patients. orthobrain`s consulting and education platform, powered by the expertise of Orthodontists, makes it faster, better, and easier than ever for general practitioners to deliver orthodontic care with confidence. With our system, your patients will obtain an Orthodontist-designed diagnosis, a step-by-step detailed treatment plan, and custom-made appliances from a trained dentist they already know and love - you! orthobrain makes it easy for you to start offering orthodontics in your practice immediately and transform your patients smiles for good.
BioSPEQ is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. Our lead program, AT-1501, is a potential best-in-class humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.
PMV is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey.
arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.